A Phase 4 interventional study of BCG vaccine and Yellow Fever vaccine in Vaccine Response Impaired, sponsored by South Australian Health and Medical Research Institute. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by South Australian Health and Medical Research Institute · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination.
The main question it aims to answer is: does depletion of the gut microbiota lead to impaired BCG-induced protection against specific and non-specific to challenges to the immune system?
The study is divided into two sub-studies. The first sub-study (BCG re-challenge) is an experimental medicine study in 168 healthy participants to determine if depletion of the gut microbiota leads to impaired BCG-induced protection against a subsequent Mycobacterium bovis BCG intradermal challenge.
The second sub-study (Yellow Fever vaccine) has a very similar experimental design to the first but will determine if depletion of the gut microbiota leads to impaired BCG-induced protection against other infections. To assess this, participants in this sub-study (n=180) will be re-challenged after 3 months with a live attenuated viral vaccine, the Yellow Fever vaccine, which induces a mild viremia.
In both sub-studies, participants will initially be randomised to receive a 3 day course of antibiotics or none (comparator group). The two groups in each sub-study will be randomised again to receive either BCG vaccine or 0.9% NaCl placebo injection in the left arm.
BCG re-challenge sub-study (Sub-study 1): Six months following randomisation, all participants will receive a BCG vaccine challenge in the right arm. A punch skin biopsy will be taken of this challenge site 2 weeks after the challenge to assess M. bovis BCG bacterial load in the skin.
Yellow Fever vaccine sub-study (Sub-study 2): Three months following randomisation, all participants will receive a Yellow Fever vaccine challenge in the right arm. Blood samples will be collected from Yellow Fever vaccinated participants at day 3, 5 and 7 following Yellow Fever vaccine challenge to quantify Yellow Fever viral load in blood.
All participants in both sub-studies will have blood samples collected at randomisation, before each vaccination, 2 weeks after each BCG vaccination and in the Yellow Fever vaccine sub-study at day 3, 5 and 7 following Yellow Fever vaccination. Stool samples will be collected prior to randomisation, and prior to each vaccination.
South Australian Health and Medical Research Institute is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
People with for BCG vaccination:
People with contraindications to YF vaccination:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Randomised to receive antibiotics and a BCG vaccine at visit 1 and a second BCG vaccine 6 months later
Biological: BCG vaccine · Drug: Vancomycin Oral Capsule · Drug: Neomycin Oral Product · Drug: Metoclopramide (Maxolon) · Drug: Loperamide HCl
Randomised to receive no antibiotics and a BCG vaccine at visit 1 and a second BCG vaccine 6 months later
Biological: BCG vaccine
Randomised to receive antibiotics, a placebo vaccine at visit 1 and a BCG vaccine 6 months later
Biological: BCG vaccine · Drug: Vancomycin Oral Capsule · Drug: Neomycin Oral Product · Drug: Metoclopramide (Maxolon) · Drug: Loperamide HCl
Randomised to receive no antibiotics, a placebo vaccine at visit 1 and a BCG vaccine 6 months later
Biological: BCG vaccine
Randomised to receive antibiotics, a BCG vaccine at visit 1 and a Yellow Fever vaccine 3 months later
Biological: BCG vaccine · Biological: Yellow Fever vaccine · Drug: Vancomycin Oral Capsule · Drug: Neomycin Oral Product · Drug: Metoclopramide (Maxolon) · Drug: Loperamide HCl
Randomised to receive no antibiotics, a BCG vaccine at visit 1 and a Yellow Fever vaccine 3 months later
Biological: BCG vaccine · Biological: Yellow Fever vaccine
Randomised to receive antibiotics, a placebo vaccine at visit 1 and a Yellow Fever vaccine 3 months later
Biological: Yellow Fever vaccine · Drug: Vancomycin Oral Capsule · Drug: Neomycin Oral Product · Drug: Metoclopramide (Maxolon) · Drug: Loperamide HCl
Randomised to receive no antibiotics, a placebo vaccine at visit 1 and a Yellow Fever vaccine 3 months later
Biological: Yellow Fever vaccine
0.1ml injected intradermally over the distal insertion of the deltoid muscle onto the humerus
0.5ml injected subcutaneously
500mg every 6 hours for 3 days
Also known as: Firvanq, Vancocin HCl Pulvules
1000mg every 6 hours for 3 days
Also known as: Neo-Fradin
10mg every 8 hours
2mg tablets/capsules: 2 tablets/capsules initially, followed by 1 tablet after each loose motion, to a maximum of 8 tablets/capsules per day
Sub-study 1 BCG re-challenge
Mycobacterial load (Colony Forming Units (CFU)/mg tissue) in the skin biopsy site in BCG-vaccinated participants not exposed to antibiotics (BCG-No ABX) compared to BCG-vaccinated participants that were exposed to antibiotics (BCG-ABX)
Time frame: 2 weeks post BCG challenge
Sub-study 2 Yellow Fever vaccine
Peak Yellow Fever viremia (viral copies/ml plasma) at day 3-7 post YFV vaccination in BCG-vaccinated participants not exposed to antibiotics (BCG-No ABX) compared to BCG-vaccinated participants that were exposed to antibiotics (BCG-ABX)
Time frame: 3, 5, 7 days post YFV challenge
Sub-study 1 - Bacterial load
Bacterial load (16S rRNA gene copies/g stool) in ABX participants compared to No-ABX participants
Time frame: Baseline (1-2 weeks before BCG/placebo vaccination), Day of vaccination and Day of BCG challenge
Sub-study 2 - Bacterial load
Bacterial load (16S rRNA gene copies/g stool) in ABX participants compared to No-ABX participants
Time frame: Baseline (1-2 weeks before BCG/placebo vaccination), Day of vaccination and Day of YFV challenge
Sub-study 1 - Microbiota diversity
Microbiota diversity (Shannon diversity index) in ABX participants compared to No-ABX participants
Time frame: Baseline (1-2 weeks before BCG/placebo vaccination), Day of vaccination and Day of BCG challenge
Sub-study 2 - Microbiota diversity
Microbiota diversity (Shannon diversity index) in ABX participants compared to No-ABX participants
Time frame: Baseline (1-2 weeks before BCG/placebo vaccination), Day of vaccination and Day of YFV challenge
Sub-study 1 - Mycobacterial load
Mycobacterial load (CFU/mg tissue) in the skin biopsy site of BCG-vaccinated participants compared to placebo-vaccinated participants
Time frame: 2 weeks post BCG challenge
Sub-study 1 - Mycobacterial-specific IFNγ responses
Mycobacterial-specific IFNγ responses (number of spot-forming units) in BCG-ABX participants compared to BCG-No ABX participants
Time frame: Baseline (1-2 weeks before BCG/placebo vaccination), 2 weeks post vaccination, Day of BCG challenge and 2 weeks post BCG challenge
Sub-study 1 - Mycobacterial-specific CD4+ T cell activation marker responses
Mycobacterial-specific T cell activation-induced marker expression (frequency of OX40+CD137+ CD4+ T cells) in BCG-ABX participants compared to BCG-No ABX participants
Time frame: Baseline (1-2 weeks before BCG/placebo vaccination), 2 weeks post vaccination, Day of BCG challenge and 2 weeks post BCG challenge
Sub-study 1 - Mycobacterial-specific CD8+ T cell activation marker responses
Mycobacterial-specific T cell activation-induced marker expression (frequency of CD69+CD137+ cells of CD8+ T cells) in BCG-ABX participants compared to BCG-No ABX participants
Time frame: Baseline (1-2 weeks before BCG/placebo vaccination), 2 weeks post vaccination, Day of BCG challenge and 2 weeks post BCG challenge
Sub-study 2 - Peak viraemia
Peak viraemia (viral copies/ml plasma) at day 3-7 post YFV challenge in BCG-vaccinated participants compared to placebo-vaccinated participants
Time frame: 3, 5 and 7 days post YFV challenge
Sub-study 2 - Heterologous TNFα responses following R848 stimulation
TNFα cytokine production (pg/mL) following stimulation of PBMC with resiquimod (R848) in BCG-ABX participants compared to BCG-No ABX participants
Time frame: Baseline (1-2 weeks before BCG/placebo vaccination) and Day of YFV challenge
Sub-study 2 - Heterologous TNFα responses following LPS stimulation
TNFα cytokine production (pg/mL) following stimulation of PBMC with lipopolysaccharide (LPS) in BCG-ABX participants compared to BCG-No ABX participants
Time frame: Baseline (1-2 weeks before BCG/placebo vaccination) and Day of YFV challenge
Sub-study 2 - Heterologous TNFα responses following HKCA stimulation
TNFα cytokine production (pg/mL) following stimulation of PBMC with heat-killed Candida albicans (HKCA) in BCG-ABX participants compared to BCG-No ABX participants
Time frame: Baseline (1-2 weeks before BCG/placebo vaccination) and Day of YFV challenge
Plan to share: Yes — Non-identifiable individual participant data from the study may be made available long-term for use by future researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept SAHMRI's conditions, under a collaborator agreement, for accessing: Individual participant data that underlie the results reported in our articles after deidentification (text, tables, figures and appendices) Study protocol, Statistical Analysis Plan, PICF Molecular data generated from this study (i.e. transcriptomic, epigenomic and metagenomic) will be labelled with a unique identification code and stored on an appropriate data repository (e.g. Gene Expression Omnibus, Sequence Read Archive) with demographic information (age and sex). No identifying participant information will be shared.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: At time of publication. Data will be available indefinitely.
Access criteria: Researchers from a recognised research institution can approach SAHMRI for access of data. The researcher will need to provide evidence that the proposed use of the data has been ethically reviewed and approved by an Institutional Review Board (IRB)/ Human Research Ethics Committee(HREC), and accept SAHMRI's conditions, under a collaborator agreement.
No publications or documents are linked to this record.
Started Nov 2023 (actual). Primary completion is estimated for Oct 2027, 46 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: BCG Vaccine · Yellow Fever Vaccine · Vancomycin · Neomycin · Metoclopramide · Loperamide
South Australian Health and Medical Research Institute